Work

A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC)

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx369.007

Authors: M. Hidalgo, R. Pazo-Cid, C. Guillen-Ponce, R. López, R. Vera, M. Reboredo, A. Muñoz, E. Martinez de Castro, R. Díaz Beveridge, A. La Casta, J.I. Martin-Valades, A. Cubillo, J. Martínez-Galán, I. Ales, J. Sastre, T. Macarulla Mercade

Institutions: Beth Israel Deaconess Medical Center, Hospital Universitario Miguel Servet, Hospital Universitario Ramón y Cajal, Complejo Hospitalario de Navarra, Complexo Hospitalario Universitario A Coruña, Hospital General Universitario Gregorio Marañón, Marqués de Valdecilla University Hospital, Hospital Universitari i Politècnic La Fe, Donostiako Unibertsitate Ospitalea, Hospital Universitario Fundación Jiménez Díaz, Hospital Universitario Virgen de las Nieves, Hospital Clínico San Carlos, Vall d'Hebron Institute of Oncology

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2764046004

FWCI: 0.728

Cites:

Cited by: 9

Related to: 10